Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Recap: WBCT Society Scientific Meeting

The Weight-Bearing CT Society held its latest Scientific Meeting in Las Vegas this past March during the AAOS 2019 conference. Co-sponsored by CurveBeam, the Scientific Meeting featured an education-packed agenda to discuss the revolutionary transformation weight-bearing technology is having on the imaging industry. First to present was Dr. Alexej Barg, MD, a University of Utah…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The Weight-Bearing CT Society held its latest Scientific Meeting in Las Vegas this past March during the AAOS 2019 conference. Co-sponsored by CurveBeam, the Scientific Meeting featured an education-packed agenda to discuss the revolutionary transformation weight-bearing technology is having on the imaging industry.

First to present was Dr. Alexej Barg, MD, a University of Utah orthopedic surgeon who also served as the moderator for this event. In his presentation discussing imaging of patients with syndesmosis instability, Dr. Barg explained that conventional non-weight-bearing radiograph imaging cannot predict syndesmotic injuries reliably. And while MRI’s demonstrate sensitivity and specificity of nearly 100%, correlating patient complaints with MRI findings can be difficult. Further, although CT technology surpasses conventional imaging methods when 3D MRI or CT imaging is transferred to 2D, there is a substantial loss of information. However, the torque applied in the natural standing position offered higher contrast and spatial resolution of alignment and degeneration, providing a significant advantage in the accuracy of diagnosing syndesmotic injuries.

Dr. Pablo Wagner, MD, of Clinica Alemana in Chile then took the stage for a presentation titled “WBCT for Assessment of Metatarsal Rotation”. Crediting his brother, Emilio Wagner, MD, for his work with hallux valgus patients, Dr. Wagner explained that metatarsal condyles are visible laterally if pronated, of which 87 percent of hallux valgus cases are. If not corrected, metatarsal pronation will result in worse clinical outcomes and higher deformity relapse rates due to the soft tissue balance lateral to the medical ray axis. However, when compared to challenging, unreliable weight-bearing axial sesamoid views and more useful AP foot weight-bearing views on plan X-Ray, weight-bearing CT scans are the gold standard in quantifying metatarsal rotations.

Following Dr. Wagner, Dr. Cesar de Cesar Netto, MD, Ph.D., discussed “WBCT in Patients with AAFD”. While some symptoms or pain are experienced in patients with Adult-Acquired Flatfoot Deformity, it can be difficult knowing when to be more aggressive in treatment to prevent foot collapse. In a study of 55 male and female patients with stage II AAFD, multiple weight bearing CBCT and MRI variables related to the severity of the deformity were evaluated. Weight-bearing CBCT was found to provide more reliability in predicting patients at high risk for foot collapse.

Dr. Arne Burssens, MD, of the Univesity Hospital of Ghent then deliberated on the “Hidden Aspects of a Medializing Calcaneus Osteotomy Revealed by a WBCT”. Difficult to assess via 2D plain radiographic technology, there is a significant difference when assessing MCO in AAFD using weight-bearing imaging versus non-weight-bearing, offering substantial detail to improve understanding with a higher rate of reliability.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512